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Influence of Surfactant Structure in the Encapsulation
and Stability of Amphotericin B in Niosomes
Claudia SALERNO 1*, Diego A. CHIAPPETTA 1,2, Ezequiel MONTEAGUDO 1 & Carlos BREGNI 1
SUMMARY. Bilayer vesicles, such as liposomes and niosomes, are widely known as efficient delivery sys-
tems for drugs. Spherical vesicles consisting of amphipatic non-ionic surfactants named niosomes are ar-
ranged in one or more concentric bilayers. They can entrap both water and oil soluble substances in the
inner aqueous phase and in the vesicular membrane, respectively. Niosomes are studied as an alternative
to liposomes because they overcome the disadvantages associated with liposomes. The present study aimed
to evaluate noisome formation from different surfactants and the encapsulation of amphotericin B as an
amphiphilic model drug. Niosomes of Span 60®, Span 80®, Glyceryl monooleate, Dehydol® LS 2 HN (lau-
ric alcohol 2EO) or Brij ®72 (Polyoxyethylene (2) Stearyl Ether) were prepared with the inclusion of
cholesterol (ratio 1:1) by a modified ether injection technique. Two concentrations, 20 and 30 mM were
studied. Span 60® and Span 80® 30mM formulations were the most stable and also the ones with higher
entrapment capacity.  
INTRODUCTION 
Niosomes are vesicles formed from the self-
assembly of non-ionic amphiphiles in aqueous
medium. Niosomes, are now widely studied as
an alternative to liposomes with lower cost, be-
cause they overcome the disadvantages associat-
ed with liposomes, such as chemical instability
and variable purity of phospholipids. There is
also a greater variety of surfactants available and
they are easy to store. Niosomes can be pre-
pared by the same procedures as of liposomes
e.g. conventional chloroform film method, re-
verse phase evaporation, ethanol injection, soni-
cation and heating method 1-5. As liposomes,
niosomes can be uni or multilamellar rounded
vesicles. 
Vesicles were considered primitive cell mod-
els and matrices for bioencapsulation. Drug en-
capsulation in addition to being modulated re-
lease systems also serves to protect bioactive
substances from degradation; for example dox-
orubicin encapsulation in C16 triglyceryl ester
niosomes was found to partially protect the
drug from photodegradation 6.
Niosomes can entrap water-soluble sub-
stances in the inner aqueous phase and oil solu-
ble substances in the vesicular membrane. En-
capsulation efficiency depends on several fac-
tors; intrinsic properties of the vesicles such as
vesicle size, cholesterol content and nature of
the membrane components and also the nature
of the solute, the hydration temperature and the
loading method used rule the encapsulation.
The vesicle structure and drug retention capabil-
ity contribute to formulation stability 1,2,6.
The first niosomes were formulated using
cholesterol and single-chain surfactants such as
alkyl oxyethylenes with the alkyl chain usually
C12–C18 long. The hydrophilic- lipophilic bal-
ance (HLB) is a good indicator of the vesicle
forming ability of any surfactant. Uchegbu et al.
reported that the sorbitan esters surfactants
(Span®) with HLB values between 4 and 8 were
compatible with vesicle formation 7. Monoalkyl
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or dialkyl chain etheric surfactants have also
been used to form niosomes, the latter are simi-
lar to phospholipids and possess higher encap-
sulation efficiency. Ester type surfactants were
also used for niosome formulation; although
these surfactants are less stable than ether type,
they possess less toxicity. Furthermore, gluco-
sides of myristil, cethyl and stearyl alcohols
were reported to form niosomes 3.
With some surfactants vesicles can only be
formed with the inclusion of cholesterol in the
bilayer. Moreover, cholesterol enhances solute
retention and stabilizes the system by prevent-
ing the formation of aggregates by repulsive
steric or electrostatic effects 3,6-9.
In recent years, nonionic surfactant vesicles
received great attention as a potential alternative
drug delivery system for both hydrophilic (e.g.
colchicine, enoxacin, salbutamol) and lipophilic
drugs (e.g. finasteride, nimesulide, dithranol).
However, the encapsulation of an amphiphilic
molecule of high molecular weight has not been
reported yet 5. 
Amphotericin B (AmB) belongs to the class
of polyene antibiotics, which are characterized
by a very low solubility of less than 1µg / mL in
water or water-free alcohols at physiological pH
(pH 6–7). AmB is water-soluble at a pH below 2
or above 11, but under such extreme conditions
the molecule is not stable. Due to its am-
phiphilic structure (Fig. 1), AmB forms aggre-
gates in water at concentrations around 2×10–M
by interaction between neighboring polyene
chains. The drug exists as a combination of
monomers, soluble and non-water soluble ag-
gregates 10,11. For parenteral injections, AmB is
often given together with sodium desoxycholate
as a solubilizing agent. In water, these two
molecules form micellar colloidal complexes.
However, only a fraction of AmB is solubilized 10.
Non-selective toxicity can be attributed to the
aggregated form of the drug. Surfactants and
some amphiphilic polymers have been demon-
strated to reduce the toxicity of AmB by de-
creasing the extent of aggregation while retain-
ing its antifungal activity 11. 
In the present work we investigated the in-
fluence of different surfactants, with a constant
ratio surfactant: cholesterol (1:1), in the encap-
sulation of AmB as an amphiphilic model drug
using a simple and inexpensive technique. Span
60® (sorbitan monostearate; Sp60), Span 80®
(sorbitan monooleate; Sp80), Monomuls® (glyc-
eryl monooleate; Glyc), Dehydol® LS 2 HN
(lauric alcohol 2EO; Dehy) and Brij 72® (Poly-
oxyethylene (2) Stearyl Ether; Brij) were used.
We also evaluated the influence of cholesterol
content in the systems that showed higher en-
trapment. 
MATERIALS AND METHODS 
Materials
Amphotericin B was a gift from Alpharma,
Argentina.  Monomuls® (Glyceryl monooleate)
and Dehydol® LS 2 HN (lauric alcohol 2EO)
were kind gift from Cognis, Argentina. Brij 72®
(Polyoxyethylene (2) Stearyl Ether) was a gift
from Croda, Argentina. Cholesterol was supplied
by Sigma, Argentina. Span 60® and Span 80®
were purchased from Parafarm, Argentina and
Sephadex G50 Sigma-Aldrich, USA. All the other
reagents were of analytical grade.
Niosomes preparation
Niosomes were prepared by a modified
ethanol injection method for liposomes de-
scribed by Batzri & Korn 3,12,13. The surfactant
and cholesterol were mixed with ethanol and
heated in a water bath until they were melted.
Then, the drug (10 mg), previously dissolved in
methanol, was added to the ethanolic solution
and the mixture was injected into a warm aque-
ous phase (40 mL) using a 14-gauge needle sy-
ringe, with continuous magnetic stirring for 20
min at 75 °C. Then the preparations were soni-
cated for 1 h, using a bath sonicator filled with
water at 60 °C. The evaporation of the solvents
(BP 78.45 and 64.65 °C for ethanol and
methanol, respectively) was evaluated by
weighing the preparations at the end of the pro-
cess. The systems were filtrated and stored in
dark glass containers.
Characterization of the systems
Microscopy and physical stability of unloaded
systems
The presence of vesicles in the samples was
observed by optical microscope (40 X) at the
Figure 1. Amphotericin B structure.
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time of preparation. The formulations were
stored at different temperature conditions, 4, 25,
and 40 °C, and evaluated by visual observation
for macroscopic changes.  
Determination of vesicle size 
The particle size of niosomes was measured at
room temperature using a Sympatec HELOS Parti-
cle size analyser with a CUVETTE adapter for the
dispersion of the samples. The lens used was R4,
with a particle size range from: 0.5/1.8 up to 350
µm). Samples were diluted with Milli-Q water to a
proper optical saturation of the equipement. Mea-
surements were made in triplicate.
Determination of entrapment efficiency
The AmB containing vesicles were separated
from the unencapsulated drug by a Sephadex G
50 column. An aliquot of 200 µL was placed and
the niosomal fraction was recovered using dis-
tilled water as eluent solvent. Vesicles were
lysed with methanol and the entrapment of the
drug was determined by UV spectrophotometry
(UV-VIS Spectrophotometer Shimadzu UV-260)
at 406 nm, using a calibration curve of AmB in
methanol covering the range 0.5-10 µg/mL (cor-
relation factor 0.9995-1.000) using methanol as
blank. Assays were done in triplicate. A solubili-
ty factor was calculated as Fs=Sa /Sw, where Sa
and Sw are the apparent solubility of AmB in the
noisome system and solubility in water, respec-
tively.
Stability of the vesicle dispersions and drug leak-
age 
Three samples of each system were kept un-
der different storage conditions: 4, 25, and 40
°C, and at fixed times they were evaluated for
drug content. Aliquots were lysed with
methanol and sonicated for 5 min. The concen-
tration of the drug was determined by UV spec-
trophotometry (see above).
Data Analysis
Data were analyzed statistically by unpaired
T-student Test, two-tailed using GraphPad InStat
(level of significance for p < 0.05). 
Surfactants Molecular weight (g/mol) MP (°C) HLB
Cholesterol 386.67 a 148–150 a 2.7 b
Span® 60 (sorbitan monostearate) 430.62 a 54-57 a 4.7 a
Span® 80 (sorbitan monooleate) 428.61 a ---- 4.3 a
Glyceryl monooleate 356.54 a 36-40 a 3.8 a
Dehydol® LS 2 HN (lauric alcohol 2EO) 274.33 c --- 6.4 d
Brij ®72 ( Polyoxyethylene (2) Stearyl Ether) 358.60 a 44-45 a 4.9 a
Table 1. Molecular weight,melting point and HLB of surfactants. a Kibbe 14; b Pasquali & Bregni 15; c supplied by
Cognis Argentina (http://www.cognis.com/countries/Argentina/sp/); d calculated according to Pasquali et al. 16.
Figure 2. Surfactants structures.
RESULTS AND DISCUSSION
Niosomes Preparation 
Niosomes of Span 60®, Span80®, Dehydol®
LS 2 HN, Glyceryl monooleate, and Brij 72®
were prepared. Figure 2 and Table 1 show
structures and physicochemical data of the sur-
factants, respectively. After preliminary studies
on total concentration of surfactants and choles-
terol, ranging from 15 to 60 mM (data not
shown), we included two final concentration of
the mixture in this study, 20 mM and 30 mM,
because they allowed proper formation of nio-
somes without sediment at the time of prepara-
tion. 
Based on previous reports we assayed 1:1
cholesterol:surfactant ratio 1,2,17,18,20. All the sur-
factants tested in the present work were able to
form vesicles in the presence of this cholesterol
ratio. The physical aspect of the formulations is
shown in Figure 3. Most vesicles were spherical
in shape (Fig. 4).
As Uchegbu and Florence 6 layed out, the as-
sociation of non-ionic surfactant monomers into
vesicles upon hydratation is a result of the high
interfacial tension between water and the hydro-
carbon portion of the amphiphile which causes
the association of these groups. Simultaneously,
the hydrophilic and/ or ionic repulsion between
the head groups ensures that these groups are
in contact with water. These two opposing
1731
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forces result in a supramolecular assembly. Fac-
tors such as surfactant structure, concentration
and temperature of the medium are important
determinants of vesicle formation. The type of
the surfactants influences encapsulation efficien-
cy and stability of niosomes. The geometric fea-
tures of amphiphilic monomer aggregation have
been analyzed by Israelachvili and a critical
packing parameter (CPP) was proposed. The
CPP is a dimensionless number that describes
the tendency of any amphiphile to form aggre-
gates, whether micellar or vesicular. According
to Eq. [1]. 
CPP = V / Ic. ao [1]
Formulation Composition SMD ± SD (µm) VMD ± SD (µm)
Sp6020mM Span60®:chol 1:1 20mM 2.79 ± 0.02 2.90 ± 0.06
Sp6030mM Span60®:chol 1:1 30mM 2.92 ± 0.00 3.10 ± 0.00
Sp8020mM Span80®:chol  1:1 20mM 1.10 ± 0.00 1.64 ± 0.00
Sp8030mM Span80®:chol 1:1  30mM 3.09 ± 0.00 3.33 ± 0.00
Dehy20mM Dehydol®LS2:chol 1:1  20mM 4.00 ± 0.00 5.87 ± 0.01
Dehy30mM Dehydol®LS2:chol 1:1  30mM 3.17 ± 0.00 3.40 ± 0.01
Glyc20mM Glyceryl monooleate:chol  1:1 20mM 1.80 ± 0.15 7.01 ± 4.91
Glyc30mM Glyceryl monooleate:chol 1:1  30mM 2.53 ± 0.06 14.57 ± 1.05
Brij20mM Brij 72®:chol 1:1  20mM 3.78 ± 0.03 11.96 ± 0.14
Brij30mM Brij 72®:chol 1:1  30mM 8.39 ± 0.08 21.00 ± 0.22
Table 2: Size of unloaded vesicles at time of preparation. Chol: cholesterol; SMD: Sauter mean diameter; VMD:
Volume median diameter.
Figure 3. Macroscopic aspect of niosomes formulations.
Figure 4. Optical microscope images of Sp6030 mM
(a), Sp8030 mM (b) and Dehy30 mM (c).
where ao = hydrophilic head group area, v = hy-
drophobic chain volume, Ic = critical hydropho-
bic chain length ( the length above which hy-
drocarbon chain fluidity may no longer be guar-
anteed), a calculated value of CPP below 0.5 in-
dicates the spherical micelle formation, values
between 0.5 and 1 indicate that the surfactant
monomers assemble preferentially into vesicles,
while a CPP of above 1 would predispose a
compound to form inverted micelles 6,8.
Characterization and stability of unloaded
systems
Large unilamellar vesicles with diameters 1-
10 µm were observed as expected, since  no ad-
ditional step was used to reduce size of the
vesicles (Table 2).
In the present work Sp60 and Sp80, which
are well known to form stable vesicles, could
form niosomes with the lowest size dispersity.
In our study size was not related to length of
the alkyl chain as reported elsewhere; more-
over, Dehy (C12) vesicles were slightly larger
than the ones in Sp60 and Sp80 (C18) formula-
tions; larger vesicles are formed when hy-
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drophilic portion of the molecule is decreased
relative to hydrophobic portion. Thus a larger
head group would also increase membrane cur-
vature and decrease vesicle size, which also ex-
plains the bigger size for Brij (C18) niosomes
compared with Sp60 and Sp80. It has been re-
ported that single alkyl tail surfactants with
higher HLB and smaller CPP can only form vesi-
cles in the presence of suitable amounts of
cholesterol, so in this case the ratio
surfactant:cholesterol 1:1 might have rendered
larger vesicles 2,3,5,18-21.
For the case of Glyceryl monooleate (C18)
we observed two populations of vesicles with
high dispersion in size (x10- x90: 0.79 ± 0.03 -
57.59 ± 0.96 µm for 20 mM formulation and x10-
x90: 0.97± 0.02 - 58.75 ± 3.94 µm for 30 mM for-
mulation); microscopic observation showed that
4 °C 25 °C 40 °C
Formulation Time (days)
0 7 15 30 60 0 7 15 30 60 0 7 15 30 60
Sp6020mM -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
Sp6030mM -- -- -- -- S -- -- -- -- -- -- -- -- -- C
Sp8020mM -- -- -- -- -- -- -- -- -- -- -- -- -- -- C
Sp8030mM -- -- -- -- -- -- -- -- -- -- -- -- -- -- --
Dehy20mM -- -- -- -- C -- -- -- -- fs -- C C C C
Dehy30mM -- -- -- -- -- -- -- -- fs fs -- fs/C fs/C fs/C fs/C
Glyc20mM -- -- -- -- S -- fs -- fs fs -- C C C C
Glyc30mM -- -- -- S S -- fs -- -- -- -- C C C C
Brij20mM -- -- -- S S -- -- fs fs S -- fs/C fs/C fs/C fs/C
Brij30mM -- S S S S -- -- fs fs S -- fs/C fs/C fs/C fs/C
Table 3. Physical appearance of niosomes at different storage conditions. -- = no change observed; S = Sedi-




Sp6020mM 10 82.87 ± 8.83 25.43 11.21
Sp6030mM 10 96.74 ± 10.82 19.70 8.73
Sp8020mM 10 63.67 ± 8.63 19.30 8.61
Sp8030mM 10 82.24 ± 4.34 16.57 7.42
Dehy20mM 10 69.86 ± 7.73 31.83 9.45
Dehy30mM 10 78.25 ± 3.18 23.77 7.06
Glyc20mM 10 57.29 ± 4.41 20.08 7.75
Glyc30mM 10 61.28 ± 8.75 14.32 5.53
Brij20mM 10 73.36 ± 10.11 24.60 9.92
Brij30mM 10 76.88 ± 8.89 17.12 6.93
Table 4. Entrapment efficiency. AmB: Amphotericin
B; Drug MW: 924.02.
AmB
(mg)
Figure 5. Glyceril monooleate (polarized light mi-
croscopy; 100 x)
part of the surfactant was unable to form vesi-
cles. Among C18 surfactants used in this study
glyceryl monooleate has the lowest HLB and al-
so according to Oda et al. C18 amphiphiles with
chiral carbons form helical ribbons 22. In Figure
5 polarized light microscopy image of glyceryl
monooleate show part of the surfactant in the
unloaded system without forming vesicles but
ribbons. 
Sp60 and Sp80 showed to be the most stable
systems when stored at 4, 25 and 40 °C. Nio-
somes have been shown to be more stable
when stored under refrigerated conditions; how-
ever, these systems remained macroscopically
stable for at least one month at 40 °C and two
months at room temperature. Table 3 reports vi-
sual changes observed. The formulations con-
taining Brij 30mM were the ones that first
1733
Latin American Journal of Pharmacy - 30 (9) - 2011
showed phase separation or sedimentation,
even at 4 °C. Glyceryl monooleate systems
showed separation in the form of flakes and be-
came more translucent at room temperature
whereas sedimentation could be observed at 4
°C. Sedimentation was greater for Brij 72® than
Glyceryl monooleate. Figure 6 shows Brij 72®
vesicles aggregated and fused after a month at
room temperature. In all cases the more concen-
trated systems showed more signs of destabiliza-
tion.
Entrapment  efficient, size and stability of
loaded systems
Table 4 shows the entrapment efficiency of
AmB, being systems Sp6030mM and Sp8030mM the
ones with more entrapment capacity. 
The average ratio of increase in the encapsu-
lation efficiency for the more concentrated sys-
tems (30mM/20mM) was 1.14, without statisti-
cally significant difference between both con-
centrations, except for Sp8030mM/Sp8020mM (p <
0.05) (Table 5). There was a significant differ-
ence in the encapsulation between of Sp60 for-
mulation and Glyc (ratio Sp6030mM/Glyc30mM =
1.58) (p<0.05). The solubility factors considered
as increment in water solubility ranged from
143.23±4.41 to 241.85 ± 10.82.
We found that vesicles obtained from long
alkyl chain (C18) surfactants are more stable
and give higher entrapment efficiency than
those obtained from shorter alkyl chain (C12)
Formulations ratio
Sp6030mM / Sp6020mM 1.17
Sp8030mM / Sp8020mM 1.29
Dehy30mM / Dehy20mM 1.12
Glyc30mM / Glyc20mM 1.07
Brij30mM / Brij20mM 1.05
Sp6030mM / Glyc30mM 1.58
Table 5. Entrapment Ratios.
Figure 6. Brij30mM vesicles after a month of storage at
room temperature.
surfactants. Surfactants with the larger hy-
drophilic head group and long alkyl chain such
as Sp60 significantly gave higher entrapment ef-
ficiency than those with the same alkyl chain
but smaller hydrophilic head group. These re-
sults are similar to the ones reported by Manos-
roi et al. 18, despite they encapsulated a water
soluble substance. It is remarkable that C18 un-
loaded formulations were more stable, but with
the inclusion of an amphiphilic drug the content
of drug was similar for both C18 and C12 sys-
tems at the end of our study. 
Sp8020mM entrapped 19.2% less than
Sp6020mM. This may be attributed to the fact that
Sp60 is solid at room temperature with a higher
phase transition temperature (Tc) 23. Sp60 and
Sp80 have the same head group, but Sp80 has
an unsaturated alkyl chain. The presence of a
double bond in the alkyl chain causes a marked
increase in the permeability of the vesicles be-
cause the molecules are bent and more separat-
ed, which might be the reason for the lower en-
trapment efficiency of Sp80 system 24. This
would also explain the case of Glyceryl
monooleate systems, which entrapped 25.6 and
35.5 % (20 and 30 mM, respectively) less than
Sp 60. Glyceryl monooleate has the same alkyl
chain length but with a double bond and also
the polar head is smaller than that of Spans.
Dehy30mM and Brij30mM entrapped 18.5 and
19.9% less than Sp6030mM, respectively, which
can be explained by the shorter alkyl chain and
much smaller polar head of Dehydol®. Al-
though Brij 72® is a C18 surfactant, its polar
head is smaller than Sp60. Dehy30mM and
Brij30mM systems entrappment capacity was simi-
lar, although the latter has a longer alkyl chain
and its polar head is twice the one of Dehy-
dol®. Polyglycerol monoalkyl and polyoxylate
ethers are the most widely used single-chain
surfactants used, however, they have less en-
capsulation efficiency even in presence of
cholesterol 3.
As mentioned, cholesterol has an important
role in vesicle formation and drug loading. It is
known that cholesterol alters the fluidity of the
chains in the bilayer when present in sufficient
concentration and eliminates the gel to liquid
phase transition endotherm of surfactant bilay-
ers 6-9. For sorbitan monoesters we studied the
influence of cholesterol ratio in the entrapment
efficiency. Figure 7 shows that for both Sp60
and Sp80 the maximum loading capacity is for
1:1 surfactant: cholesterol ratio. Balakrishnan P
et al. studied the influence of cholesterol for mi-
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noxidil niosomes, and showed similar results.
The increment in the encapsulation in presence
of cholesterol may be due to increase in the
lipophilic behavior of the lipid bilayer which
may lead to better trapping of hydrophobic or
amphiphilic drugs. However, at higher concen-
tration of cholesterol (1:1.5), it may compete
with the drug for packing space within the bi-
layer as amphiphilic moieties assemble into
vesicles 5,25.
Table 6 shows sizes of loaded vesicles. Load-
ed niosomes of Sp6030mM and Sp8030mM were
3.04 and 2.84 µm, respectively which could be
explained by the amphiphilic structure of AmB
with polar groups located along one side of the
molecule. Because of the influence of HLB val-
ue and CPP in a potential niosome system the
presence of an amphipathic or hydrophobic
drug must be taken into account as both these
substances are to be incorporated into the vesi-
cle membrane 8,25. For AmB molecules the abili-
ty to form cylindrical molecular aggregates fol-
lows directly from its stereochemical structure
(Fig. 1). Gruszecki et al. showed modified pack-
ing of the drug in the presence of a lipid com-
ponent. Self-organization of AmB in a polar and
hydrophobic environment was the subject of
numerous recent theoretical and experimental
studies. In particular, the organization of AmB
in the environment of lipid membranes has
been recently addressed as directly relevant to
the pharmacological efectiveness of the drug 26. 
Furthermore, Dehydol® and Brij 72® loaded
vesicles were smaller than unloaded ones,
which may be explained by the influence of the
addition of an amphipathic drug, similar to what
Pardakhty et al. reported for the effect of adding
cholesterol to Brij 52® (C16)  niosomes, increas-
ing hydrophobicity of the surfactant mixture led
to a smaller vesicle size 24,27. In Figure 8 the im-
Figure 7. Influence of surfactant:cholesterol ratio in
the encapsulation of AmB for systems Sp6030mM and
Sp8030mM.
Formulation SMD ± SD (µm) VMD ± SD (µm)
Sp6020mM 1.08 ± 0.04 2.68 ± 0.02
Sp6030mM 3.04 ± 0.02 3.28 ± 0.03
Sp8020mM 1.35 ± 0.05 3.05 ± 0.04
Sp8030mM 2.84 ± 0.10 3.04 ± 0.08
Dehy20mM 2.87 ± 0.00 3.09 ± 0.01
Dehy30mM 1.04 ± 0.01 2.73 ± 0.02
Glyc20mM 2.98 ± 0.05 3.26 ± 0.91
Glyc30mM 1.44 ± 0.12 1.71 ± 0.04
Brij20mM 2.99 ± 0.05 3.25 ± 0.09
Brij30mM 3.40 ± 0.01 4.39 ± 0.06
Table 6. Size of loaded vesicles at time of prepara-
tion. SMD: Sauter mean diameter; VMD: Volume me-
dian diameter.
age of AmB loaded Glyc30mM shows irregular
vesicles without spherical shape; interestingly,
loaded system had only one vesicles population,
showing the effect of the loaded drug in the as-
sembly of the bilayer.
Figures 9, 10 and 11 show the stability of
loaded formulations at the different storage con-
ditions 4, 25 and 40 °C. As expected systems
were more stable at refrigerated conditions both
because of the vesicles and the drug stability it-
self, but it is worth noting that drug content in
Dehydol® vesicles remain stable after 90 days in
a similar extent  to Span 60® and Span 80®.
This might be explained by the stabilization ef-
fect of the amphiphilic drug compared with the
Figure 8. Gly30mM AmB  loaded vesicles (polarized
light microscopy).
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empty vesicles. Even more, Dehydol® vesicles
were more stable than sorbitan monoesters for-
mulations at 25 °C. Glyceryl monooleate and
Brij 72® resulted to be the least stable systems.
The results of drug retention studies show
greater drug leakage at higher temperature. This
may be due to the increased fluidity of lipid bi-
layers at higher temperature resulting in greater
drug leakage 7. The stability of niosomes sys-
tems might be improved by incorporating into a
gel base which may prevent of fusion of vesi-
cles and at the same time the formulation would
be appropriate for topical use. 
Figure 9. Stability of loaded systems at 4 °C.
Figure 10. Stability of loaded systems at 25 °C.
Figure 11. Stability of loaded systems at 40 °C.
CONCLUSION
Amphotericin B as an amphiphilic model
drug could be entrapped in various non-ionic
surfactants vesicles in the presence of choles-
terol, with a simple technique. Sorbitan mo-
noestearate vesicles showed the highest trap-
ping efficiency. The systems could retain 70% of
the loaded drug at 4°C for three months. Further
investigations incorporating a gelling agent are
to be performed to improve drug retention and
to evaluate topical application. 
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